TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18089770
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous doses of PC-SOD (40-160 mg)
Study: 18089770
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of PC-SOD (80 mg for 7 days)
Study: 18089770
Drug: Single 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 80 mg dose of PC-SOD
Study: 9186076
Drug: Fosinopril and
Normalized name: fosinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril and Lisinopril (combined with furosemide)
Study: 9186076
Drug: Fosinopril and
Normalized name: fosinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril and Lisinopril (in blacks)
Study: 9186076
Drug: Fosinopril and
Normalized name: fosinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril and Lisinopril (in nonblacks)
Study: 3911700
Drug: Oxycone-papaverine 5+50
Normalized name: papaverine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycone-papaverine 5+50 mg
Study: 29762909
Drug: Dichlorphenamide, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichlorphenamide, single doses of 25‐400 mg followed by 50‐800 mg/day for 10 doses.
Study: 29762909
Drug: Dichlorphenamide, up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichlorphenamide, up to 28 titrated doses from 100‐800 mg/day (Cohort F).
Study: 29762909
Drug: Cohorts A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts A, B, and C (doses of 25-400 mg and 50-800 mg/day).
Study: 27063319
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at effect‐site concentration of 1.5 ng/mL
Study: 24486089
Drug: Telaprevir plus
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir plus peginterferon/ribavirin therapy
Study: 22482335
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg daily for 8 weeks
Study: 20579335
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behaviour therapy (CBT) for anxiety disorders
Study: 20579335
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behaviour therapy (CBT) for depression
Study: 20579335
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behaviour therapy (CBT) for mixed anxiety and depression
Study: 20579335
Drug: Problem solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem solving therapy (PST) for depression and mixed anxiety and depression
Study: 17270528
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drugs (control)
Study: 9109134
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily ceftriaxone plus amikacin
Study: 9109134
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily ceftazidime plus amikacin
Study: 22048173
Drug: HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6)
Study: 22048173
Drug: HPV-6/11/16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-6/11/16/18 vaccine (Gardasil® Merck & Co., Inc., Months 0, 2, 6)
Study: 8704686
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) therapy
Study: 1388172
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment methods for lateral epicondylitis
Study: 1388172
Drug: Placebo effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo effect of all treatments
Study: 24293167
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (2 g before surgery and 500 mg twice daily for 5 days after surgery)
Study: 24293167
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C
Study: 23733308
Drug: SOC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC plus mefloquine (250 mg for 3 days, then 250 mg weekly)
Study: 20886185
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg BID starting 12-24 hours postoperatively)
Study: 20886185
Drug: TAK-442 10
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 10 mg BID
Study: 20886185
Drug: TAK-442 20
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 20 mg BID
Study: 20886185
Drug: TAK-442 40
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 40 mg QD
Study: 20886185
Drug: TAK-442 40
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 40 mg BID
Study: 20886185
Drug: TAK-442 80
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 80 mg QD
Study: 20886185
Drug: TAK-442 80
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 80 mg BID
Study: 20886185
Drug: TAK-442 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 (all doses except 10 and 20 mg BID)
Study: 18634152
Drug: High-dose iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose iloprost (up to 2 ng/kg body weight per minute)
Study: 18634152
Drug: Low-dose iloprost
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iloprost (0.5 ng/kg body weight per minute)
Study: 18634152
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and low-dose iloprost
Study: 18634152
Drug: High-dose iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose iloprost
Study: 18634152
Drug: Low-dose iloprost
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iloprost
Study: 14637388
Drug: Tumour marker
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour marker guided treatment (salvage treatment)
Study: 14637388
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (after radiological confirmation of metastases)
Study: 23414120
Drug: Erythropoietin intravenous
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin intravenous (EIV) group
Study: 23414120
Drug: Erythropoietin subcutaneous
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin subcutaneous (ESC) group
Study: 21719898
Drug: Yogurt supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt supplement (YOG; n = 15)
Study: 17209212
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements for cancer prevention
Study: 17209212
Drug: Nutritional agents
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional agents
Study: 16281923
Drug: Valacyclovir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir treatment
Study: 29425398
Drug: Child therapy
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child therapy
Study: 12049443
Drug: Combined child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined child therapy and parent/teacher training
Study: 9855591
Drug: Intravenous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioids (meperidine)
Study: 9855591
Drug: Intravenous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioids (compliant patients)
Study: 1976938
Drug: Grapefruit Pill
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit Pill
Study: 1976938
Drug: Natural Vitality
Normalized name: Vital-Chlor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural Vitality pill
Study: 24646
Drug: Lorazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (mean dose of approximately 3 mg on a b.i.d. regimen)
Study: 28391283
Drug: Soy drink
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy drink (250 mL, 12 mg isoflavones)
Study: 28391283
Drug: Decaffeinated black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated black tea (300 mL, 67 mg catechins)
Study: 28391283
Drug: Water (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (300 mL, control)
Study: 25811794
Drug: Gastroretentive gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gastroretentive gabapentin (G-GR) 1800 mg once-daily
Study: 23902431
Drug: Cynatine(®) HNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cynatine(®) HNS (500 mg keratin plus vitamins and minerals)
Study: 19046856
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (IVIP)
Study: 8279842
Drug: Surgical adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical adjuvant chemotherapy for colorectal cancer; details on dosage and duration not available.
Study: 15797167
Drug: Standard RAVLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard RAVLT administration (true recognition + primacy recognition)
Study: 11817496
Drug: Anticraving drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticraving drug expectancy
Study: 7554698
Drug: Chloroguanide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroguanide (200 mg orally)
Study: 7554698
Drug: Chloroguanide with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroguanide with omeprazole (40 mg/day for 7 days)
Study: 7554698
Drug: Mephenytoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mephenytoin (100 mg orally)
Study: 2202384
Drug: Zabicipril 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabicipril 2.5 mg
Study: 2202384
Drug: Zabicipril (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabicipril (0.03 to 10 mg)
Study: 22828124
Drug: saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 2.5 mg q.A.M.
Study: 22828124
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg q.A.M.
Study: 22828124
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg q.P.M.
Study: 22828124
Drug: saxagliptin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin (all doses)
Study: 20980999
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg with high-fat meal
Study: 20980999
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg with low-fat meal
Study: 20980999
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg with high-fat meal
Study: 11952027
Drug: Emedastine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine plus placebo capsules
Study: 11952027
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of emedastine and loratadine
Study: 10551714
Drug: Propionyl-L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (1 g bid, p.o.)
Study: 8635265
Drug: TAK-044 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 (10 to 1000 mg IV over a 15-minute period)
Study: 8635265
Drug: TAK-044 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 (30, 250, and 750 mg IV)
Study: 8635265
Drug: TAK-044 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 (1000 mg)
Study: 1947791
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg three times daily for 6 days
Study: 1947791
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 6 days
Study: 6339137
Drug: Chymopapain injection
Normalized name: Chymopapain
DrugBank: Chymopapain (DB06752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chymopapain injection (4000 IU, 2 ml)
Study: 21316537
Drug: Voriconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (200 mg BID orally after a loading dose of 400 mg BID on day 1)
Study: 21316537
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg BID orally, no loading dose)
Study: 18553458
Drug: R1626 500
Normalized name: R1626
DrugBank: R1626 (DB05060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1626 500 mg
Study: 18553458
Drug: R1626 1500
Normalized name: R1626
DrugBank: R1626 (DB05060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1626 1500 mg
Study: 18553458
Drug: R1626 3000
Normalized name: R1626
DrugBank: R1626 (DB05060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1626 3000 mg
Study: 18553458
Drug: R1626 4500
Normalized name: R1626
DrugBank: R1626 (DB05060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R1626 4500 mg
Study: 16491958
Drug: SCDSF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCDSF treatment
Study: 10811079
Drug: Vigabatrin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin monotherapy
Study: 10811079
Drug: Carbamazepine monotherapy
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine monotherapy
Study: 6360703
Drug: Inhalation powder
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder (1 mg fenoterol, 5 doses of 0.2 mg over 10 minutes)
Study: 6360703
Drug: Pressurized aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurized aerosol (1 mg fenoterol, 5 doses of 0.2 mg over 10 minutes)
Study: 30449623
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2 on days 1, 22, and 43 of radiotherapy)
Study: 30449623
Drug: Cetuximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (400 mg/m2 loading dose followed by seven weekly infusions of 250 mg/m2)
Study: 10599151
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone replacement therapy
Study: 29959763
Drug: No recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No recombinant human growth hormone replacement therapy
Study: 29959763
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment and cranial radiotherapy
Study: 29959763
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment outcomes
Study: 26861603
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg daily for 5 years
Study: 24402594
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (clear liquid diet and two self-administered saline enemas)
Study: 21922153
Drug: Paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel monotherapy (T)
Study: 19116178
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin plus low-dose aspirin
Study: 3011257
Drug: Etoposide (VP-16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP-16) at 300 mg/m2
Study: 3011257
Drug: Etoposide (VP-16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP-16) at 600 mg/m2
Study: 3011257
Drug: Etoposide (VP-16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP-16) at 900 mg/m2
Study: 28864675
Drug: G-tube placement
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-tube placement
Study: 25977146
Drug: Trimethoprim‐sulfamethoxazole 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim‐sulfamethoxazole 320 mg/1600 mg twice daily
Study: 25977146
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g twice daily
Study: 16732143
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of dexamethasone
Study: 16732143
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily doses of dexamethasone
Study: 15465501
Drug: Tai chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai chi training (1‐hour class held twice weekly for 12 weeks)
Study: 15465501
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (pharmacologic therapy and dietary and exercise counseling)
Study: 11394516
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% (100 mg in 7.5% glucose)
Study: 11394516
Drug: Procaine 10%
Normalized name: procaine 10% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine 10% (100 mg diluted with 1 ml cerebrospinal fluid)
Study: 9555823
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin cream (commercially available)
Study: 7672871
Drug: Amikacin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (15 mg/kg per day) given in one (qd, n = 10) or two equal injections (b.i.d., n = 12) for durations of 7‐11 days
Study: 7672871
Drug: Amikacin (qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (qd and b.i.d. administration)
Study: 2646469
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy (IIT) with free mixtures of regular and intermediate (12 hrs)‐acting insulin
Study: 2646469
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy (IIT) with basal and prandial insulin treatment (preprandial injections of regular insulin, and ultralente (24 hrs‐acting) or intermediate insulin for basal demand)
Study: 25693010
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin
Study: 26202150
Drug: Novel recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel recombinant human FSH (rhFSH, FE 999049) at doses of 5·2‐12·1 μg/day
Study: 20028262
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravitreal ranibizumab (IVR) injection
Study: 15105192
Drug: Metoprolol 10
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 10 mg
Study: 15105192
Drug: Metoprolol 20
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 20 mg
Study: 15105192
Drug: Metoprolol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 30 mg
Study: 11368733
Drug: Salmeterol xinafoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate, 42 microg twice per day (salmeterol‐minus group)
Study: 11368733
Drug: Salmeterol xinafoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate, 42 microg twice per day (salmeterol‐plus group)
Study: 9038597
Drug: RRR-alpha-tocopherol and
Normalized name: RRR-alpha-tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR-alpha-tocopherol and RRR-alpha-tocopheryl acetate (administered in equal doses)
Study: 8316388
Drug: Bier's block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bier's block with 0.6 mg of atropine in 10 ml of saline
Study: 3555034
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg orally every 12 hours (or 500 mg for the 13-year-old) for 2 to 8 weeks
Study: 3555034
Drug: Tobramycin and
Normalized name: Tobramycin and Dexamethasone Ophthalmic Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin and azlocillin administered intravenously for at least two weeks
Study: 26554670
Drug: Transcranial Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Direct Current Stimulation (tDCS) in addition to Tinnitus Retraining Therapy (TRT)
Study: 26554670
Drug: Sham Transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Transcranial Direct Current Stimulation (tDCS) in addition to Tinnitus Retraining Therapy (TRT)
Study: 23589371
Drug: Preladenant 5
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 5 mg twice a day
Study: 16921788
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2 mg/day for 12 weeks
Study: 16921788
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 microg/day (7-day patches) for 12 weeks
Study: 16921788
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between oral and transdermal therapy
Study: 3669283
Drug: Cefuzonam (CZON)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuzonam (CZON) administered by intravenous injection or intravenous drip infusion, 1 g twice daily for 4 to 7 days (8 g to 14 g in total)
Study: 26410046
Drug: Carotid endarterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid endarterectomy (CEA) with modern medical treatment (MMT)
Study: 26410046
Drug: Modern medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern medical treatment (MMT) alone
Study: 21397567
Drug: Alemtuzumab (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (24 mg per day or 12 mg per day intravenously for 2 or 3 annual cycles)